Stockreport

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism [Yahoo! Fin...

Lantern Pharma Inc.  (LTRN) 
PDF solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand [Read more]